Gaedigk A - Search Results

1

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.

Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T. Theken KN, et al. Among authors: gaedigk a. Clin Pharmacol Ther. 2020 Aug;108(2):191-200. doi: 10.1002/cpt.1830. Epub 2020 Apr 28. Clin Pharmacol Ther. 2020. PMID: 32189324 Free PMC article.

2

Interethnic differences of drug-metabolizing enzymes.

Gaedigk A. Gaedigk A. Int J Clin Pharmacol Ther. 2000 Feb;38(2):61-8. doi: 10.5414/cpp38061. Int J Clin Pharmacol Ther. 2000. PMID: 10706192 Review.

3

Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.

Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr. Kim JS, et al. Among authors: gaedigk a. J Clin Pharmacol. 2001 Jul;41(7):715-22. doi: 10.1177/00912700122010618. J Clin Pharmacol. 2001. PMID: 11452703 Clinical Trial.

4

Omeprazole disposition in children following single-dose administration.

Kearns GL, Andersson T, James LP, Gaedigk A, Kraynak RA, Abdel-Rahman SM, Ramabadran K, van den Anker JN. Kearns GL, et al. Among authors: gaedigk a. J Clin Pharmacol. 2003 Aug;43(8):840-8. doi: 10.1177/0091270003256122. J Clin Pharmacol. 2003. PMID: 12953341 Clinical Trial.

5

Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events.

Gaedigk A, Ndjountché L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, Brousseau DC, McCarver DG, Johnson JA, Alander SW, Wayne Riggs K, Steven Leeder J. Gaedigk A, et al. Clin Pharmacol Ther. 2007 Feb;81(2):242-51. doi: 10.1038/sj.clpt.6100033. Clin Pharmacol Ther. 2007. PMID: 17259947

6

Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.

Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Blake MJ, et al. Among authors: gaedigk a. Clin Pharmacol Ther. 2007 Apr;81(4):510-6. doi: 10.1038/sj.clpt.6100101. Epub 2007 Feb 14. Clin Pharmacol Ther. 2007. PMID: 17301735

7

Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype.

Gaedigk A, Eklund JD, Pearce RE, Leeder JS, Alander SW, Phillips MS, Bradford LD, Kennedy MJ. Gaedigk A, et al. Clin Pharmacol Ther. 2007 Jun;81(6):817-20. doi: 10.1038/sj.clpt.6100125. Epub 2007 Mar 28. Clin Pharmacol Ther. 2007. PMID: 17392730

8

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. Gaedigk A, et al. Clin Pharmacol Ther. 2008 Feb;83(2):234-42. doi: 10.1038/sj.clpt.6100406. Epub 2007 Oct 31. Clin Pharmacol Ther. 2008. PMID: 17971818

9

Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype.

Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI. Leeder JS, et al. Among authors: gaedigk a. J Clin Pharmacol. 2008 Sep;48(9):1041-51. doi: 10.1177/0091270008319709. J Clin Pharmacol. 2008. PMID: 18728242 Free PMC article.

10

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.

Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U. Abduljalil K, et al. Among authors: gaedigk a. Clin Pharmacol Ther. 2010 Nov;88(5):643-51. doi: 10.1038/clpt.2010.137. Epub 2010 Sep 29. Clin Pharmacol Ther. 2010. PMID: 20881950 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page